Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region.
@article{Mehrtash2018ComparativeAO,
title={Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region.},
author={Hedieh Mehrtash and Richard Laing and Veronika J. Wirtz},
journal={Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit},
year={2018},
volume={24 5},
pages={
427-434
}
}Background
Adequate access to essential medicines for cardiovascular disease is necessary to address the high cardiovascular disease burden in countries of the Eastern Mediterranean Region of the World Health Organization (WHO).
Aims
This study compared the cardiovascular disease medicines included in the WHO Model Essential Medicines List with those in the national essential medicines lists of 19 countries of the Region.
Methods
Data were extracted on the number of cardiovascular medicines…
One Citation
Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists
- Medicine, Political SciencePloS one
- 2019
The majority of priority medicines for NCDs described within key WHO NCD technical packages are listed on nearly all national EMLs across 137 countries of all income levels.
References
SHOWING 1-10 OF 12 REFERENCES
International Variations In Essential Medication Lists
- Medicine, Political Science
- 2014
It was noted that on average most of the countries studied were lacking 47% of medications, and had 30% additional medications on their national formulary, compared to the Essential Medication Lists.
Selection of oncology medicines in low- and middle-income countries.
- MedicineAnnals of oncology : official journal of the European Society for Medical Oncology
- 2014
The observed selection of oncology essential medicines can reflect insufficiencies and inequalities in access to cancer treatments at least in the public sector of LMICs, as explored through investigating national essential medicines lists for cancer treatments.
25 years of the WHO essential medicines lists: progress and challenges
- Medicine, Political ScienceThe Lancet
- 2003
Challenges in managing infections among pediatric cancer patients: Suboptimal national essential medicines lists for low and middle income countries
- MedicinePediatric blood & cancer
- 2015
The selection of antimicrobial agents for national essential medicines lists in LMICs warrants attention from a pediatric cancer perspective and frequency and corresponding 95% confidence limits are assessed.
Essential medicines for breast cancer in low and middle income countries
- MedicineBMC Cancer
- 2015
Alignment of selection with guidelines’ recommendations was inconsistent for different types of early and advanced breast cancer in NEMLs and regular updates and more attention to clinical guidelines is recommended.
Changes in the World Health Organisation essential drug list
- Medicine, Political ScienceThe Lancet
- 1991
Response by Wirtz et al to Letter Regarding Article, "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries".
- MedicineCirculation
- 2016
There is a dearth of published information about the quality of noncommunicable disease medicines including cardiovascular medicines, and a major incident led to the establishment of the Judicial Inquiry Tribunal to determine the cause of contamination in 2011.
Health and ecological sustainability in the Arab world: a matter of survival
- Political ScienceThe Lancet
- 2014




